LA JOLLA, Calif. , May 11, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (NASDAQ:KURA) a clinical stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2016 . “Kura has made important progress in advancing its pipeline of precision oncology drug
Management to Host Webcast and Conference Call Today at 4:30 p.m. EDT LA JOLLA, Calif. , March 17, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (NASDAQ:KURA) a clinical stage biopharmaceutical company, today announced highlights and financial results for the fourth quarter and full year ended
LA JOLLA, Calif. , March 11, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that it will report fourth quarter and full year 2015 financial results after the close of U.S. financial markets on March 17, 2016 .
LA JOLLA, Calif. , Feb. 04, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, will participate in a fireside chat at 2:15 p.m. ET ( 11:15 a.m.
Tipifarnib as Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients With High Risk Disease LA JOLLA, Calif. , Dec. 3, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that new data from
LA JOLLA, Calif. , Dec. 1, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, will present an overview of the company at 10:55 a.m. EST ( 7:55 a.m.
LA JOLLA, Calif. , Nov. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, will present an overview of the company at 11:30 a.m. EST ( 8:30 a.m.
LA JOLLA, Calif. , Nov. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), today announced that the first patient has been dosed in an investigator-sponsored Phase 2 trial of its lead drug candidate, tipifarnib, an inhibitor of protein farnesylation, in cancer patients with urothelial
LA JOLLA, Calif. , Nov. 11, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, will present an overview of the company at 2:40 p.m. GMT ( 6:40 a.m.
LA JOLLA, Calif. , Nov. 4, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced the pricing of its public offering of 6,250,000 shares of common
